UA71621C2 - Use of combined bacterial composition as dietary or pharmaceutical supplement for preventing or treating hyperoxaluria - Google Patents

Use of combined bacterial composition as dietary or pharmaceutical supplement for preventing or treating hyperoxaluria Download PDF

Info

Publication number: UA71621C2
Authority: UA; Ukraine
Prior art keywords: strain; composition; hyperoxaluria; bacterial; dietary
Prior art date: 1999-05-28

Application number

UA2001129040A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Vsl Pharma Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-28

Filing date

2000-05-24

Publication date

2004-12-15

2000-05-24 Application filed by Vsl Pharma Ltd filed Critical Vsl Pharma Ltd

2004-12-15 Publication of UA71621C2 publication Critical patent/UA71621C2/uk

Links

208000008852 Hyperoxaluria Diseases 0.000 title claims abstract description 32
239000000203 mixture Substances 0.000 title claims abstract description 29
235000005911 diet Nutrition 0.000 title claims abstract description 12
230000000378 dietary effect Effects 0.000 title claims abstract description 8
230000001580 bacterial effect Effects 0.000 title claims description 10
239000013589 supplement Substances 0.000 title description 2
241000894006 Bacteria Species 0.000 claims abstract description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
208000035475 disorder Diseases 0.000 claims description 10
241001465754 Metazoa Species 0.000 claims description 5
244000005700 microbiome Species 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 5
238000004113 cell culture Methods 0.000 claims description 4
238000000034 method Methods 0.000 claims description 3
238000012876 topography Methods 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 abstract description 4
241000186012 Bifidobacterium breve Species 0.000 abstract 1
240000001046 Lactobacillus acidophilus Species 0.000 abstract 1
235000013956 Lactobacillus acidophilus Nutrition 0.000 abstract 1
240000001929 Lactobacillus brevis Species 0.000 abstract 1
235000013957 Lactobacillus brevis Nutrition 0.000 abstract 1
240000006024 Lactobacillus plantarum Species 0.000 abstract 1
235000013965 Lactobacillus plantarum Nutrition 0.000 abstract 1
241000194020 Streptococcus thermophilus Species 0.000 abstract 1
229940039695 lactobacillus acidophilus Drugs 0.000 abstract 1
229940072205 lactobacillus plantarum Drugs 0.000 abstract 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 28
150000003891 oxalate salts Chemical class 0.000 description 22
210000002700 urine Anatomy 0.000 description 15
VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 13
238000010521 absorption reaction Methods 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
239000008103 glucose Substances 0.000 description 7
230000000968 intestinal effect Effects 0.000 description 7
210000000936 intestine Anatomy 0.000 description 7
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
239000011575 calcium Substances 0.000 description 6
229910052791 calcium Inorganic materials 0.000 description 6
235000010633 broth Nutrition 0.000 description 5
238000000354 decomposition reaction Methods 0.000 description 5
229920001817 Agar Polymers 0.000 description 4
206010029148 Nephrolithiasis Diseases 0.000 description 4
244000299461 Theobroma cacao Species 0.000 description 4
239000008272 agar Substances 0.000 description 4
239000003833 bile salt Substances 0.000 description 4
229940093761 bile salts Drugs 0.000 description 4
230000037213 diet Effects 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
241000723382 Corylus Species 0.000 description 3
235000007466 Corylus avellana Nutrition 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
208000004777 Primary Hyperoxaluria Diseases 0.000 description 3
244000300264 Spinacia oleracea Species 0.000 description 3
235000009337 Spinacia oleracea Nutrition 0.000 description 3
244000269722 Thea sinensis Species 0.000 description 3
QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 3
239000003925 fat Substances 0.000 description 3
235000019197 fats Nutrition 0.000 description 3
235000013305 food Nutrition 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
239000008101 lactose Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
235000006408 oxalic acid Nutrition 0.000 description 3
238000002271 resection Methods 0.000 description 3
239000004575 stone Substances 0.000 description 3
235000013616 tea Nutrition 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
238000009631 Broth culture Methods 0.000 description 2
229920001268 Cholestyramine Polymers 0.000 description 2
201000003883 Cystic fibrosis Diseases 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
208000000913 Kidney Calculi Diseases 0.000 description 2
235000009470 Theobroma cacao Nutrition 0.000 description 2
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
229960003459 allopurinol Drugs 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
235000019219 chocolate Nutrition 0.000 description 2
230000000112 colonic effect Effects 0.000 description 2
235000015872 dietary supplement Nutrition 0.000 description 2
201000010099 disease Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000029142 excretion Effects 0.000 description 2
HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
210000003405 ileum Anatomy 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
210000002429 large intestine Anatomy 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
208000009304 Acute Kidney Injury Diseases 0.000 description 1
244000003416 Asparagus officinalis Species 0.000 description 1
235000005340 Asparagus officinalis Nutrition 0.000 description 1
235000016068 Berberis vulgaris Nutrition 0.000 description 1
241000335053 Beta vulgaris Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
235000002566 Capsicum Nutrition 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
241000792859 Enema Species 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
240000009088 Fragaria x ananassa Species 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
241000758791 Juglandaceae Species 0.000 description 1
235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
206010030302 Oliguria Diseases 0.000 description 1
241000758706 Piperaceae Species 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
244000299790 Rheum rhabarbarum Species 0.000 description 1
235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
240000003768 Solanum lycopersicum Species 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
206010041969 Steatorrhoea Diseases 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
208000003728 Vulvodynia Diseases 0.000 description 1
206010069055 Vulvovaginal pain Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000002535 acidifier Substances 0.000 description 1
229940095602 acidifiers Drugs 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
230000003355 alkalizing urine Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003579 anti-obesity Effects 0.000 description 1
239000000883 anti-obesity agent Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
BWKOZPVPARTQIV-UHFFFAOYSA-N azanium;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [NH4+].OC(=O)CC(O)(C(O)=O)CC([O-])=O BWKOZPVPARTQIV-UHFFFAOYSA-N 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940069978 calcium supplement Drugs 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
238000012321 colectomy Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000004601 colonic permeability Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000007882 dietary composition Nutrition 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
244000038280 herbivores Species 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
239000000416 hydrocolloid Substances 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
201000006334 interstitial nephritis Diseases 0.000 description 1
230000031891 intestinal absorption Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
229940091250 magnesium supplement Drugs 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
201000000173 nephrocalcinosis Diseases 0.000 description 1
235000016236 parenteral nutrition Nutrition 0.000 description 1
230000008289 pathophysiological mechanism Effects 0.000 description 1
235000021400 peanut butter Nutrition 0.000 description 1
230000035699 permeability Effects 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000001508 potassium citrate Substances 0.000 description 1
229960002635 potassium citrate Drugs 0.000 description 1
QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
235000011082 potassium citrates Nutrition 0.000 description 1
235000012015 potatoes Nutrition 0.000 description 1
108010009004 proteose-peptone Proteins 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
210000004767 rumen Anatomy 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
241000894007 species Species 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
208000001162 steatorrhea Diseases 0.000 description 1
235000021012 strawberries Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
230000000450 urinary calcium excretion Effects 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
235000020234 walnut Nutrition 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
235000015099 wheat brans Nutrition 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Microbiology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Mycology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Nutrition Science (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Steroid Compounds (AREA)

UA2001129040A 1999-05-28 2000-05-24 Use of combined bacterial composition as dietary or pharmaceutical supplement for preventing or treating hyperoxaluria UA71621C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT1999RM000338A IT1309427B1 (it)	1999-05-28	1999-05-28	Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
PCT/IT2000/000213 WO2000072855A2 (fr)	1999-05-28	2000-05-24	Composition alimentaire ou pharmaceutique utilisee pour prevenir ou traiter l'hyperoxalurie

Publications (1)

Publication Number	Publication Date
UA71621C2 true UA71621C2 (en)	2004-12-15

Family

ID=11406789

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2001129040A UA71621C2 (en)	1999-05-28	2000-05-24	Use of combined bacterial composition as dietary or pharmaceutical supplement for preventing or treating hyperoxaluria

Country Status (34)

Country	Link
US (2)	US6562336B2 (fr)
EP (1)	EP1181027B1 (fr)
JP (1)	JP4737836B2 (fr)
KR (1)	KR100781703B1 (fr)
CN (1)	CN100350919C (fr)
AR (1)	AR024555A1 (fr)
AT (1)	ATE265857T1 (fr)
AU (1)	AU773459B2 (fr)
BR (1)	BR0011038B1 (fr)
CA (1)	CA2373255C (fr)
CZ (1)	CZ20014076A3 (fr)
DE (1)	DE60010456T2 (fr)
DK (1)	DK1181027T3 (fr)
DZ (1)	DZ3165A1 (fr)
EA (1)	EA004257B1 (fr)
EE (1)	EE200100618A (fr)
ES (1)	ES2219344T3 (fr)
HK (1)	HK1048066B (fr)
HU (1)	HU225134B1 (fr)
IL (3)	IL146703A0 (fr)
IS (1)	IS6150A (fr)
IT (1)	IT1309427B1 (fr)
MA (1)	MA26790A1 (fr)
MX (1)	MXPA01012184A (fr)
NO (1)	NO20015782L (fr)
NZ (1)	NZ516020A (fr)
PL (1)	PL352014A1 (fr)
PT (1)	PT1181027E (fr)
SI (1)	SI1181027T1 (fr)
SK (1)	SK16612001A3 (fr)
TR (1)	TR200103439T2 (fr)
UA (1)	UA71621C2 (fr)
WO (1)	WO2000072855A2 (fr)
ZA (1)	ZA200110504B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1283225B1 (it) *	1996-03-11	1998-04-16	Renata Maria Anna Ve Cavaliere	Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
US8486389B2 (en) *	1997-05-23	2013-07-16	Oxthera, Inc.	Compositions and methods for treating or preventing oxalate-related disease
US8697051B2 (en) *	1999-06-09	2014-04-15	Vsl Pharmaceuticals Inc.	Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
ITRM20010763A1 (it) *	2001-12-21	2003-06-21	Simone Claudio De	Nuovo ceppo di batterio lattico e composizioni commestibili, farmaci e prodotti veterinari che lo contengono.
US20050074442A1 (en) *	2002-03-13	2005-04-07	Natarajan Ranganathan	Compositions and methods for augmenting kidney function
US11103542B2 (en)	2002-03-13	2021-08-31	Kibow Biotech, Inc.	Composition and method for maintaining healthy kidney function
US9655932B2 (en)	2002-03-13	2017-05-23	Kibow Biotech, Inc.	Composition and method for preventing or treating gout or hyperuricemia
EP1649863A1 (fr) *	2003-06-24	2006-04-26	Otsuka Pharmaceutical Co., Ltd.	Composition pour diminuer le taux d'acide urique serique
US20050158294A1 (en)	2003-12-19	2005-07-21	The Procter & Gamble Company	Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en)	2003-12-19	2014-11-04	The Iams Company	Methods of use of probiotic bifidobacteria for companion animals
WO2005089564A1 (fr)	2004-03-19	2005-09-29	Danisco A/S	Composition emulsifiante a raccourcir
US7468182B2 (en) *	2004-10-27	2008-12-23	North Carolina State University	Lactobacillus acidophilus nucleic acids and uses thereof
AU2006253007B2 (en)	2005-05-31	2012-12-20	Alimentary Health Ltd	Feline probiotic Bifidobacteria
EP2261323A1 (fr)	2005-05-31	2010-12-15	The Iams Company	Lactobacilles probiotiques félins
WO2007070052A2 (fr) *	2005-12-14	2007-06-21	Oxthera, Inc.	Compositions pharmaceutiques et méthodes destinées à traiter ou prévenir une maladie associée à l'oxalate
JP5558002B2 (ja)	2005-12-16	2014-07-23	オクセラインコーポレイテッド	シュウ酸塩低減化のための組成物および方法
US20080241226A1 (en) *	2007-03-27	2008-10-02	Abeln Susan L	Methods and Kits For Administering Probiotics
US9771199B2 (en)	2008-07-07	2017-09-26	Mars, Incorporated	Probiotic supplement, process for making, and packaging
CN101606952B (zh) *	2008-06-17	2012-09-19	上海交通大学医学院附属第三人民医院	乳双歧杆菌在制备预防泌尿系统结石药物中的应用
US9283252B2 (en)	2008-09-30	2016-03-15	Meiji Co., Ltd.	Lactic acid bacterium having high oxalic acid decomposition ability
CN101554237B (zh) *	2009-03-16	2013-11-06	武汉康复得生物科技有限公司	植物纤维或微生物不溶组分中的草酸降解酶的制备方法
US10104903B2 (en)	2009-07-31	2018-10-23	Mars, Incorporated	Animal food and its appearance
IT1403661B1 (it)	2011-01-28	2013-10-31	Probiotical Spa	Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
ITMI20110793A1 (it)	2011-05-09	2012-11-10	Probiotical Spa	Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITMI20110792A1 (it)	2011-05-09	2012-11-10	Probiotical Spa	Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITMI20110791A1 (it)	2011-05-09	2012-11-10	Probiotical Spa	Ceppi di batteri in grado di metabolizzare gli ossalati.
ITRM20110477A1 (it)	2011-09-09	2013-03-10	Giovanni Mogna	Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell
ITMI20111718A1 (it)	2011-09-23	2013-03-24	Probiotical Spa	Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
ITMI20121173A1 (it) *	2012-07-04	2014-01-05	Neupharma Srl	Composizioni dietetiche e/o farmaceutiche comprendenti ceppi di lactobacillus e bifidobacterium capaci di degradare gli ossalati e di indurre una risposta immunitaria di tipo anti-infiammatorio
ITMI20130795A1 (it) *	2013-05-14	2014-11-15	Probiotical Spa	Composizione comprendente batteri lattici e/o bifidobatteri per uso nel trattamento preventivo e/o curativo delle infezioni batteriche e/o delle infiammazioni del tratto urinario e/o della prostata che sono la causa di prostatiti e ipertrofia prostat
ITMI20130793A1 (it) *	2013-05-14	2014-11-15	Probiotical Spa	Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
JP5765832B2 (ja) *	2013-12-26	2015-08-19	雪印メグミルク株式会社	加齢に伴う代謝異常症の予防・改善・治療剤
CA2963213C (fr) *	2014-10-01	2021-02-09	Triphase Pharmaceuticals Pvt. Ltd.	Souches de lactobacillus thermostables, produits et methodes associes
ITUB20155752A1 (it)	2015-11-19	2017-05-19	Probiotical Spa	Composizione di batteri per uso per attenuare le diminuzioni di prestazione dopo un esercizio fisico che danneggia i muscoli.
ITUA20162013A1 (it)	2016-03-24	2017-09-24	Probiotical Spa	Composizione a base di batteri lattici per il trattamento contemporaneo di infezioni vaginali di origine micotica e batterica.
CN107868776A (zh)	2016-09-23	2018-04-03	武汉康复得生物科技股份有限公司	糖基化草酸脱羧酶及其制备和应用
US11179426B2 (en)	2016-12-29	2021-11-23	Kibow Biotech, Inc.	Composition and method for maintaining healthy kidney function
US12421518B2 (en)	2018-12-10	2025-09-23	Tenza, Inc.	Methods and compositions for treating hyperoxaluria
BR112022013867A2 (pt) *	2020-01-14	2022-09-13	Synlogic Operating Co Inc	Bactérias manipuladas para tratar distúrbios nos quais o oxalato é prejudicial
CN113308416B (zh) *	2021-07-20	2023-02-24	四川大学	一株具有抑制肾结石形成能力的植物乳杆菌及其应用
CN115851508B (zh) *	2022-10-13	2024-01-09	山东中科嘉亿生物工程有限公司	一种降草酸、改善肾结石的嗜热链球菌jyst-26及其产品、应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5810520A (ja) *	1981-07-10	1983-01-21	Miyarisan Kk	胆石症の治療薬
DE69219768T2 (de) *	1992-07-06	1997-08-28	Societe Des Produits Nestle S.A., Vevey	Milchbakterien
IT1283225B1 (it) *	1996-03-11	1998-04-16	Renata Maria Anna Ve Cavaliere	Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
ATE169456T1 (de) *	1996-12-23	1998-08-15	Sitia Yomo Spa	Lyophilisierte, lebende bakerien enthaltende nahrungszusammensetzung
JP4996780B2 (ja) *	1997-05-23	2012-08-08	オクセラインコーポレイテッド	シュウ酸塩関連疾患を予防するためのシュウ酸塩分解微生物またはシュウ酸塩分解酵素
RU2139346C1 (ru) *	1999-03-02	1999-10-10	Шендеров Борис Аркадьевич	Штамм бактерий lactobacillus plantarum, обладающий способностью снижать уровень оксалата и используемый для приготовления препаратов и продуктов питания для профилактики и лечения гипероксалурии

1999
- 1999-05-28 IT IT1999RM000338A patent/IT1309427B1/it active
2000
- 2000-05-24 MX MXPA01012184A patent/MXPA01012184A/es active IP Right Grant
- 2000-05-24 DE DE60010456T patent/DE60010456T2/de not_active Expired - Lifetime
- 2000-05-24 BR BRPI0011038-8A patent/BR0011038B1/pt not_active IP Right Cessation
- 2000-05-24 IL IL14670300A patent/IL146703A0/xx unknown
- 2000-05-24 UA UA2001129040A patent/UA71621C2/uk unknown
- 2000-05-24 CA CA002373255A patent/CA2373255C/fr not_active Expired - Fee Related
- 2000-05-24 SK SK1661-2001A patent/SK16612001A3/sk unknown
- 2000-05-24 EE EEP200100618A patent/EE200100618A/xx unknown
- 2000-05-24 HK HK03100152.1A patent/HK1048066B/zh not_active IP Right Cessation
- 2000-05-24 DK DK00935478T patent/DK1181027T3/da active
- 2000-05-24 CZ CZ20014076A patent/CZ20014076A3/cs unknown
- 2000-05-24 DZ DZ003165A patent/DZ3165A1/fr active
- 2000-05-24 AU AU51016/00A patent/AU773459B2/en not_active Ceased
- 2000-05-24 EA EA200101262A patent/EA004257B1/ru not_active IP Right Cessation
- 2000-05-24 NZ NZ516020A patent/NZ516020A/xx unknown
- 2000-05-24 HU HU0201409A patent/HU225134B1/hu not_active IP Right Cessation
- 2000-05-24 KR KR1020017014857A patent/KR100781703B1/ko not_active Expired - Fee Related
- 2000-05-24 AT AT00935478T patent/ATE265857T1/de active
- 2000-05-24 SI SI200030363T patent/SI1181027T1/xx unknown
- 2000-05-24 WO PCT/IT2000/000213 patent/WO2000072855A2/fr not_active Ceased
- 2000-05-24 ES ES00935478T patent/ES2219344T3/es not_active Expired - Lifetime
- 2000-05-24 PL PL00352014A patent/PL352014A1/xx not_active Application Discontinuation
- 2000-05-24 PT PT00935478T patent/PT1181027E/pt unknown
- 2000-05-24 EP EP00935478A patent/EP1181027B1/fr not_active Expired - Lifetime
- 2000-05-24 CN CNB008081824A patent/CN100350919C/zh not_active Expired - Fee Related
- 2000-05-24 AR ARP000102552A patent/AR024555A1/es not_active Application Discontinuation
- 2000-05-24 JP JP2000620965A patent/JP4737836B2/ja not_active Expired - Fee Related
- 2000-05-24 TR TR2001/03439T patent/TR200103439T2/xx unknown
2001
- 2001-11-08 MA MA26402A patent/MA26790A1/fr unknown
- 2001-11-08 IS IS6150A patent/IS6150A/is unknown
- 2001-11-22 IL IL146703A patent/IL146703A/en not_active IP Right Cessation
- 2001-11-26 US US09/992,029 patent/US6562336B2/en not_active Ceased
- 2001-11-27 NO NO20015782A patent/NO20015782L/no not_active Application Discontinuation
- 2001-12-21 ZA ZA200110504A patent/ZA200110504B/xx unknown
2005
- 2005-02-04 US US11/050,623 patent/USRE39585E1/en not_active Expired - Lifetime
2009
- 2009-06-18 IL IL199437A patent/IL199437A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
WO2000072855A3 (fr)	2001-06-28
CA2373255C (fr)	2010-01-19
HK1048066A1 (zh)	2003-03-21
KR100781703B1 (ko)	2007-12-03
US6562336B2 (en)	2003-05-13
IT1309427B1 (it)	2002-01-23
ES2219344T3 (es)	2004-12-01
CA2373255A1 (fr)	2000-12-07
NZ516020A (en)	2003-06-30
EE200100618A (et)	2003-02-17
SI1181027T1 (en)	2004-08-31
PT1181027E (pt)	2004-09-30
IL199437A0 (en)	2011-07-31
BR0011038A (pt)	2002-02-26
DK1181027T3 (da)	2004-08-16
JP2003500451A (ja)	2003-01-07
DZ3165A1 (fr)	2000-12-07
HU225134B1 (en)	2006-06-28
TR200103439T2 (tr)	2002-06-21
BR0011038B1 (pt)	2014-02-18
ATE265857T1 (de)	2004-05-15
MXPA01012184A (es)	2003-06-30
SK16612001A3 (sk)	2002-04-04
KR20020019918A (ko)	2002-03-13
WO2000072855A2 (fr)	2000-12-07
EA004257B1 (ru)	2004-02-26
USRE39585E1 (en)	2007-04-24
JP4737836B2 (ja)	2011-08-03
IS6150A (is)	2001-11-08
EA200101262A1 (ru)	2002-04-25
DE60010456D1 (de)	2004-06-09
EP1181027B1 (fr)	2004-05-06
AU773459B2 (en)	2004-05-27
ITRM990338A0 (it)	1999-05-28
HUP0201409A3 (en)	2004-10-28
AU5101600A (en)	2000-12-18
DE60010456T2 (de)	2005-05-12
IL199437A (en)	2016-10-31
CN100350919C (zh)	2007-11-28
IL146703A0 (en)	2002-07-25
US20020061292A1 (en)	2002-05-23
HUP0201409A2 (en)	2002-08-28
AR024555A1 (es)	2002-10-16
NO20015782L (no)	2002-01-25
CN1365284A (zh)	2002-08-21
ZA200110504B (en)	2002-09-25
IL146703A (en)	2010-03-28
CZ20014076A3 (cs)	2002-03-13
MA26790A1 (fr)	2004-12-20
PL352014A1 (en)	2003-07-14
HK1048066B (zh)	2008-08-01
ITRM990338A1 (it)	2000-11-28
EP1181027A2 (fr)	2002-02-27
NO20015782D0 (no)	2001-11-27

Publication	Publication Date	Title
UA71621C2 (en)	2004-12-15	Use of combined bacterial composition as dietary or pharmaceutical supplement for preventing or treating hyperoxaluria
Sadaf et al.	2017	Role of gut microbiota against calcium oxalate
US5531989A (en)	1996-07-02	Immunoglobulin and fiber-containing composition for human gastrointestinal health
Ferraz et al.	2009	Effects of Lactobacillus casei and Bifidobacterium breve on urinary oxalate excretion in nephrolithiasis patients
AU2008310961B2 (en)	2014-08-28	Probiotics for use in relieving symptoms associated with gastrointestinal disorders
AU2011314299B2 (en)	2015-01-29	Compositions and methods for augmenting kidney function
JP2005013211A (ja)	2005-01-20	乳酸菌含有食品組成物
US7026160B2 (en)	2006-04-11	Oral bacteriotherapy compositions and methods
KR100523661B1 (ko)	2005-10-24	결장 내에서 프로피온산 및/또는 프로피오네이트를생성하기 위한 프로피온 박테리아의 용도
US20120177622A1 (en)	2012-07-12	Renal-function-ameliorating agent
US20160354419A9 (en)	2016-12-08	Probiotics for use in relieving symptoms associated with gastrointestinal disorders
Kumar et al.	0	Effect of feeding synbiotic products on the faecal flora of albino rats and healthy volunteers
HK1146914B (en)	2013-07-19	Pharmaceutical compositions comprising l. acidophilus and bifidobacterium lactis for use in the treatment of functional bowel disorder